Home > Topoisomerase & > Daunorubicin HCl

Daunorubicin HCl

盐酸佐柔比星,盐酸柔红霉素,Daunomycin HCl

Daunorubicin Hydrochloride 能抑制DNA和RNA合成，对DNA合成的Ki为0.02 μM。

目录号
EY1751
EY1751
EY1751
EY1751
纯度
99.37%
99.37%
99.37%
99.37%
规格
5 mg
10 mg
50 mg
100 mg
原价
315
491
1560
2380
售价
315
491
1560
2380
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM.

  • 体外研究

  • 体内研究

    Saline

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Gewirtz DA, et al. Biochem Pharmacol, 1999, 57(7), 727-741.
    [2] Trieb, M., et al. 2004. J. Biomol. Struct. Dyn. 21: 713-724.
    [3] Weiss, R.B. 1992. Semin. Oncol. 19: 670-686.
    [4] Taatjes, D.J., et al. 1996. J. Med. Chem. 39: 4135-4138.

    分子式
    C27H30ClNO10    		 分子量
    563.98    		 CAS号
    23541-50-6    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    ≥80 mg/mL    		 Water
    ≥80 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT02914977 Acute Lymphocytic Leukemia|Acute Myeloid Leukemia Drug: Daunorubicin University of Kansas Medical Center Phase 1 2016-11-01 2016-11-04
    NCT01265199 Acute Myelogenous Leukemia (AML) Drug: AT-406 in combination with daunorubicin and cytarabine Ascenta Therapeutics|The Leukemia and Lymphoma Society Phase 1 2011-02-01 2013-01-21
    NCT00427414 Sarcoma Drug: liposomal daunorubicin citrate AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation Phase 1 2008-09-01 2015-04-28
    NCT01999413 Acute Myeloid Leukemia (AML) Drug: OMEGAVEN|Drug: Daunorubicin|Drug: Cytarabine French Innovative Leukemia Organisation|Fresenius Kabi Phase 2 2013-11-01 2016-10-25
    NCT01804101 Acute Biphenotypic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Untreated Adult Acute Myeloid Leukemia Other: Laboratory Biomarker Analysis|Drug: Liposomal Cytarabine-Daunorubicin CPX-351 Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) 2013-04-01 2017-01-11
    NCT00673257 Unspecified Childhood Solid Tumor, Protocol Specific Drug: daunorubicin hydrochloride|Other: pharmacological study|Procedure: dual x-ray absorptimetry Children's Oncology Group|National Cancer Institute (NCI) 2007-01-01 2016-09-06
    NCT00474006 ACUTE MYELOGENOUS LEUKEMIA Drug: arm II Cooperative Study Group A for Hematology Phase 3 2001-08-01 2011-06-08
    NCT00589082 AML|Elderly Drug: DaunoXome|Drug: Daunorubicine Gruppo Italiano Malattie EMatologiche dell'Adulto Phase 3 2001-10-01 2008-01-08
    NCT02403310 Leukemia|Acute Myeloid Leukemia|AML Drug: Selinexor|Drug: Daunorubicin|Drug: Cytarabine H. Lee Moffitt Cancer Center and Research Institute|Karyopharm Therapeutics, Inc Phase 1 2015-06-01 2016-12-13
    NCT02971397 Acute Myeloid Leukemia Procedure: Bone Marrow Aspiration and Biopsy|Drug: Cytarabine|Drug: Daunorubicin Hydrochloride|Other: Laboratory Biomarker Analysis Wake Forest University Health Sciences|National Cancer Institute (NCI) 2016-11-01 2017-01-17
    NCT01463046 Acute Myeloid Leukemia|Advanced Myelodysplastic Syndrome Drug: Panobinostat|Drug: Cytarabine|Drug: Daunorubicin University of California, San Francisco|Novartis Phase 1 2012-01-01 2016-01-11
    NCT01806571 Untreated Adult Acute Myeloid Leukemia Drug: Cytarabine|Drug: Daunorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Nilotinib|Other: Pharmacological Study Mayo Clinic|National Cancer Institute (NCI) Phase 2 2015-03-12 2017-03-21
    NCT00814164 Leukemia Drug: clofarabine|Drug: daunorubicin hydrochloride|Genetic: cytogenetic analysis|Genetic: protein expression analysis|Other: immunologic technique|Other: pharmacological study Roswell Park Cancer Institute|Genzyme, a Sanofi Company Phase 2 2008-12-01 2016-07-07
    NCT00715637 Secondary Acute Myeloid Leukemia (Secondary AML, sAML) Drug: Daunorubicin and Cytarabine|Drug: Amonafide and Cytarabine Antisoma Research Phase 3 2007-06-01 2010-10-12
    NCT00005942 Chronic Myelomonocytic Leukemia|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation Drug: liposomal daunorubicin citrate|Drug: semaxanib|Other: laboratory biomarker analysis National Cancer Institute (NCI) Phase 1|Phase 2 2000-03-01 2013-01-22
    NCT00927498 Acute Myeloid Leukemia Drug: conventional chemotherapy (AraC + Daunorubicin),|Drug: Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin), Acute Leukemia French Association|Versailles Hospital Phase 3 2007-12-01 2013-07-10
    NCT01145846 Acute Myelogenous Leukemia Drug: Cytarabine plus Daunorubicin [Arm II (AD regimen)] Cooperative Study Group A for Hematology Phase 3 2010-05-01 2010-06-16
    NCT00085124 Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia Biological: oblimersen sodium|Drug: cytarabine|Drug: daunorubicin hydrochloride|Other: laboratory biomarker analysis National Cancer Institute (NCI) Phase 3 2003-12-01 2013-06-04

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：